FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808830456> ?p ?o ?g. }

• W2808830456 endingPage "454" @default.
• W2808830456 startingPage "443" @default.
• W2808830456 abstract "To date, no efficacious therapy exists that will prevent or treat the severe osteoporosis in individuals with neurologically motor-complete spinal cord injury (SCI). Recent preclinical studies have demonstrated that sclerostin antibody (Scl-Ab) can prevent sublesional bone loss after acute SCI in rats. However, it remains unknown whether sclerostin inhibition reverses substantial bone loss in the vast majority of the SCI population who have been injured for several years. This preclinical study tested the efficacy of Scl-Ab to reverse the bone loss that has occurred in a rodent model after chronic motor-complete SCI. Male Wistar rats underwent either complete spinal cord transection or only laminectomy. Twelve weeks after SCI, the rats were treated with Scl-Ab at 25 mg/kg/week or vehicle for 8 weeks. In the SCI group that did not receive Scl-Ab, 20 weeks of SCI resulted in a significant reduction of bone mineral density (BMD) and estimated bone strength, and deterioration of bone structure at the distal femoral metaphysis. Treatment with Scl-Ab largely restored BMD, bone structure, and bone mechanical strength. Histomorphometric analysis showed that Scl-Ab increased bone formation in animals with chronic SCI. In ex vivo cultures of bone marrow cells, Scl-Ab inhibited osteoclastogenesis, and promoted osteoblastogenesis accompanied by increased Tcf7, ENC1, and the OPG/RANKL ratio expression, and decreased SOST expression. Our findings demonstrate for the first time that Scl-Ab reverses the sublesional bone loss when therapy is begun after relatively prolonged spinal cord transection. The study suggests that, in addition to being a treatment option to prevent bone loss after acute SCI, sclerostin antagonism may be a valid clinical approach to reverse the severe bone loss that invariably occurs in patients with chronic SCI." @default.
• W2808830456 created "2018-06-29" @default.
• W2808830456 creator A5003738856 @default.
• W2808830456 creator A5009652803 @default.
• W2808830456 creator A5010449479 @default.
• W2808830456 creator A5011751744 @default.
• W2808830456 creator A5016299584 @default.
• W2808830456 creator A5022709890 @default.
• W2808830456 creator A5032396875 @default.
• W2808830456 creator A5035291764 @default.
• W2808830456 creator A5037367559 @default.
• W2808830456 creator A5043311300 @default.
• W2808830456 creator A5073780815 @default.
• W2808830456 creator A5080647612 @default.
• W2808830456 creator A5083340084 @default.
• W2808830456 date "2018-06-21" @default.
• W2808830456 modified "2023-10-03" @default.
• W2808830456 title "Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury" @default.
• W2808830456 cites W1497274320 @default.
• W2808830456 cites W1595394563 @default.
• W2808830456 cites W1717043261 @default.
• W2808830456 cites W1829322399 @default.
• W2808830456 cites W1955609192 @default.
• W2808830456 cites W1968000966 @default.
• W2808830456 cites W1981030744 @default.
• W2808830456 cites W1983220846 @default.
• W2808830456 cites W1984821835 @default.
• W2808830456 cites W1987188857 @default.
• W2808830456 cites W1991218860 @default.
• W2808830456 cites W1992510000 @default.
• W2808830456 cites W1996161852 @default.
• W2808830456 cites W1998758244 @default.
• W2808830456 cites W2002725330 @default.
• W2808830456 cites W2009046507 @default.
• W2808830456 cites W2011828467 @default.
• W2808830456 cites W2017210822 @default.
• W2808830456 cites W2027667550 @default.
• W2808830456 cites W2038636807 @default.
• W2808830456 cites W2043991983 @default.
• W2808830456 cites W2051484890 @default.
• W2808830456 cites W2052499629 @default.
• W2808830456 cites W2054603232 @default.
• W2808830456 cites W2057249403 @default.
• W2808830456 cites W2065519748 @default.
• W2808830456 cites W2068916684 @default.
• W2808830456 cites W2085100544 @default.
• W2808830456 cites W2087423776 @default.
• W2808830456 cites W2092966571 @default.
• W2808830456 cites W2107277218 @default.
• W2808830456 cites W2113523811 @default.
• W2808830456 cites W2119934014 @default.
• W2808830456 cites W2121729624 @default.
• W2808830456 cites W2134473688 @default.
• W2808830456 cites W2146084470 @default.
• W2808830456 cites W2147478863 @default.
• W2808830456 cites W2148991704 @default.
• W2808830456 cites W2149286305 @default.
• W2808830456 cites W2152136687 @default.
• W2808830456 cites W2161984225 @default.
• W2808830456 cites W2163341100 @default.
• W2808830456 cites W2209135845 @default.
• W2808830456 cites W2221806096 @default.
• W2808830456 cites W2398309765 @default.
• W2808830456 cites W2486745824 @default.
• W2808830456 cites W2767906784 @default.
• W2808830456 cites W4296537467 @default.
• W2808830456 doi "https://doi.org/10.1007/s00223-018-0439-8" @default.
• W2808830456 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7891854" @default.
• W2808830456 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29931461" @default.
• W2808830456 hasPublicationYear "2018" @default.
• W2808830456 type Work @default.
• W2808830456 sameAs 2808830456 @default.
• W2808830456 citedByCount "23" @default.
• W2808830456 countsByYear W28088304562018 @default.
• W2808830456 countsByYear W28088304562019 @default.
• W2808830456 countsByYear W28088304562020 @default.
• W2808830456 countsByYear W28088304562021 @default.
• W2808830456 countsByYear W28088304562022 @default.
• W2808830456 countsByYear W28088304562023 @default.
• W2808830456 crossrefType "journal-article" @default.
• W2808830456 hasAuthorship W2808830456A5003738856 @default.
• W2808830456 hasAuthorship W2808830456A5009652803 @default.
• W2808830456 hasAuthorship W2808830456A5010449479 @default.
• W2808830456 hasAuthorship W2808830456A5011751744 @default.
• W2808830456 hasAuthorship W2808830456A5016299584 @default.
• W2808830456 hasAuthorship W2808830456A5022709890 @default.
• W2808830456 hasAuthorship W2808830456A5032396875 @default.
• W2808830456 hasAuthorship W2808830456A5035291764 @default.
• W2808830456 hasAuthorship W2808830456A5037367559 @default.
• W2808830456 hasAuthorship W2808830456A5043311300 @default.
• W2808830456 hasAuthorship W2808830456A5073780815 @default.
• W2808830456 hasAuthorship W2808830456A5080647612 @default.
• W2808830456 hasAuthorship W2808830456A5083340084 @default.
• W2808830456 hasBestOaLocation W28088304562 @default.
• W2808830456 hasConcept C104317684 @default.
• W2808830456 hasConcept C118552586 @default.
• W2808830456 hasConcept C126322002 @default.
• W2808830456 hasConcept C134018914 @default.

• next